Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2021 / Cilt: 29 - Sayı: 3

Raising the bar to ultradisciplinary collaborations in management of chronic thromboembolic pulmonary hypertension

Kronik tromboembolik pulmoner hipertansiyon tedavisinde çıtayı ultradisipliner iş birliğine yükseltmek

Pages
417–731
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Management strategies for the “new normal” such as virtual care, preparedness for further threats, redesigned standards and working conditions, reevaluation of specific recommendations, and online collaborations for optimal decisions for chronic thromboembolic pulmonary hypertension patients may change the poor outcomes

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic thromboembolic pulmonary hypertension is an underdiagnosed and potentially fatal subgroup of pulmonary hypertension, if left untreated.
📊
Key Findings & Data:Targeted medical therapy and balloon pulmonary angioplasty can be effective in high-risk patients with significant comorbidities, distal pulmonary vascular obstructions, or recurrent/persistent pulmonary hypertension after pulmonary endarterectomy.
💡
Conclusion & Impact:Management strategies for the “new normal” such as virtual care, preparedness for further threats, redesigned standards and working conditions, reevaluation of specific recommendations, and online collaborations for optimal decisions for chronic thromboembolic pulmonary hypertension patients may change the poor outcomes
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Chronic thromboembolic pulmonary hypertension is an underdiagnosed and potentially fatal subgroup of pulmonary hypertension, if left untreated. Clinical signs include exertional dyspnea and non-specific symptoms. Diagnosis requires multimodality imaging and heart catheterization. Pulmonary endarterectomy, an open heart surgery, is the gold standard treatment of choice in selected patients in specialized centers. Targeted medical therapy and balloon pulmonary angioplasty can be effective in high-risk patients with significant comorbidities, distal pulmonary vascular obstructions, or recurrent/persistent pulmonary hypertension after pulmonary endarterectomy. Currently, there is a limited number of data regarding novel coronavirus-2019 infection in patients with chronic thromboembolic pulmonary hypertension and the changing spectrum of the disease during the pandemic. Challenging times during this outbreak due to healthcare crisis and relatively higher case-fatality rates require convergence; that is an ultradisciplinary collaboration, which crosses disciplinary and sectorial boundaries to develop integrated knowledge and new paradigms. Management strategies for the “new normal” such as virtual care, preparedness for further threats, redesigned standards and working conditions, reevaluation of specific recommendations, and online collaborations for optimal decisions for chronic thromboembolic pulmonary hypertension patients may change the poor outcomes

Özet

Kronik tromboembolik pulmoner hipertansiyon, yetersiz oranda tanı konulan ve tedavi edilmez ise potansiyel olarak ölümcül olabilen bir pulmoner hipertansiyon alt grubudur. Klinik bulguları efor dispnesi ve spesifik olmayan semptomlardır. Tanı için, multimodal görüntüleme ve kalp kateterizasyonu gerekmektedir. Bir açık kalp ameliyatı olan pulmoner endarterektomi, uzman merkezlerde seçilmiş hastalar için uygulanan altın standart tedavi şeklidir. Hedeflenmiş tıbbi tedavi ve balon pulmoner anjiyoplasti, belirgin komorbiditeleri olan yüksek riskli hastalarda, distal pulmoner vasküler tıkanıklıklarda veya pulmoner endarterektomi sonrası nüks eden veya inatçı pulmoner hipertansiyonda etkili olabilir. Günümüzde kronik tromboembolik pulmoner hipertansiyonlu hastalarda yeni koronavirüs-2019 enfeksiyonuna ve hastalığın pandemi sırasında değişen spektrumuna ilişkin veriler sınırlıdır. Bu pandemi sırasında sağlık hizmetleri krizi nedeniyle yaşanan zor zamanlar ve göreceli olarak artmış ölüm oranları, birleşmeyi, diğer bir deyişle, disiplinler arası ve sektörel sınırları geçerek, birleşik bilgileri ve yeni paradigmaları geliştirebilmek için ultradisipliner iş birliğini zorunlu kılmaktadır. ‘’Yeni normal’’ dönemde sanal bakım, daha ileri tehditler için hazırlıklı olma, yeniden düzenlenen standartlar, spesifik önerilerin tekrar değerlendirilmesi ve kronik tromboembolik pulmoner hipertansiyon hastaları için en iyi kararı verebilmek üzere çevrimiçi iş birlikleri gibi tedavi stratejileri, kötü prognozu değiştirebili

🔖

Cite This Article

Doğan, R., Biçer, M., İspir, S., Yanartaş, M., Kaymaz, C., Yağdı, T., Şırlak, M., Orhan, G., Gültekin, B., Akay, T., Kervan, Ü., Akar, A. R., Taş, S. G. (2022). Raising the bar to ultradisciplinary collaborations in management of chronic thromboembolic pulmonary hypertension. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 29 - Sayı: 3, 417–731. https://ajindex.com/articles/423593

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for thediagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015;46:903-75
  2. Wilkens H, Konstantinides S, Lang IM, Bunck AC, Gerges M, Gerhardt F, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018;272S:69-78
  3. Taş SG. Pulmoner hipertansiyon. In: Polat A, Akay HT, Köksal C, Bozkurt AK, editörler. Damar. İstanbul: Bayçınar Tıbbi Yayıncılık; 2019. s. 663-76
  4. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915
  5. Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev 2017;26:170105
  6. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation 2014;130:508-18
  7. Mahmud E, Madani MM, Kim NH, Poch D, Ang L, Behnamfar O, et al. Chronic thromboembolic pulmonary hypertension: Evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol 2018;71:2468-86
  8. Klok FA, Barco S, Konstantinides SV, Dartevelle P, Fadel E, Jenkins D, et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: Results from the European CTEPH Registry. Eur Respir J 2018;52:1801687
  9. Akay HT, Hatipoğlu A. Kronik tromboembolik pulmoner hipertansiyon. In: Polat A, Akay HT, Köksal C, Bozkurt AK, editörler. Damar. İstanbul: Bayçınar Tıbbi Yayıncılık; 2019. s. 677-87
  10. Uçanok K, Akar AR. Septostomi ve pulmoner tromboendarterektomi. In: Karabıyıkoğlu G, editör. Pulmoner hipertansiyon. Ankara: Antıb Basımevi; 2007. s. 244-56
  11. Okumuş G, Önen ZP, editörler. Pulmoner hipertansiyon Tanı ve Tedavi Uzlaşı Raporu. İstanbul: Logos Yayıncılık; 2020
  12. Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011;183:1605-13
  13. Khangoora VS, Shlobin OA. Evolving spectrum of treatment for CTEPH. Curr Opin Pulm Med 2020;26:406-13
  14. Auger WR, Fedullo PF. Chronic thromboembolic